TPST
Tempest Therapeutics Inc
NASDAQ: TPST · HEALTHCARE · BIOTECHNOLOGY
$0.54
+5.72% today
Updated 2026-10-28
Market cap
$8.63M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-3.93
Dividend yield
—
52W range
$1 – $11
Volume
3.2M
WallStSmart proprietary scores
17
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C4.5
Quality
C3.0
Profitability
D5.0
Valuation
C+3/9
Piotroski F-Score
Weak
-23.6
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →270 stocks currently score above 75
Price targets
Analyst target
$7.00
+1196.54%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
Price chart
Stock snapshot
Strengths
+ Debt/equity -6.94x — low leverage
Risks
- Piotroski 3/9 — weak financial health
- Altman Z -23.63 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-2.78M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-35.71M | $-29.49M | $-41.84M | $-26.26M | $-5.24M |
| EPS | — | — | — | — | $-3.93 |
| Free cash flow | $-31.63M | $-27.53M | $-33.46M | $-26.82M | $-2.78M |
| Profit margin | — | — | — | — | — |
Peer comparison
Smart narrative
Tempest Therapeutics Inc trades at $0.54. Our Smart Value Score of 17/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of -23.63, it sits in the distress.
Frequently asked questions
What is Tempest Therapeutics Inc's stock price?
Tempest Therapeutics Inc (TPST) trades at $0.54.
Is Tempest Therapeutics Inc overvalued?
Tempest Therapeutics Inc carries a Smart Value Score of 17/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Tempest Therapeutics Inc (TPST)?
The 12-month analyst consensus target is $7.00, about 1196.5% above the current $0.54. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Altman Z-Score?
Tempest Therapeutics Inc's Altman Z-Score is -23.63, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE-203.60%
Beta-1.71
50D MA$0.87
200D MA$1.56
Shares out0.02B
Float0.01B
Short ratio—
Avg volume3.2M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—